(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 July 2007 (05.07.2007)

PCT

(10) International Publication Number
WO 2007/076354 A3

(51) International Patent Classification:
*A61K 38/17* (2006.01) *C07K 14/705* (2006.01)

(21) International Application Number:
PCT/US2006/062297

(22) International Filing Date:
19 December 2006 (19.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/752,150 20 December 2005 (20.12.2005) US

(71) Applicant *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DALI, Manisha, M.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **DAHLHEIM, Charles, E.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **BORSADIA, Sunita** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **NARINGREKAR, Vijay, H.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **GANDHI, Rajesh, B.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **NERURKAR, Manoj** [US/IN]; 601B Devare House, Bhavanishankar Road, Dadar, Mumbai 400028 (IN).

(74) Agents: **PARLET, Nickki, L.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

(88) Date of publication of the international search report:
16 August 2007

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: STABLE PROTEIN FORMULATIONS

(57) Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous(SC) for treating immune system diseases and tolerance induction.

WO 2007/076354 A3